TOP TEN perturbations for 39773_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39773_at
Selected probe(set): 202562_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39773_at (202562_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):2.7149105
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

rosuvastatin study 1 (48h) / rifampicin study 5 (48h)

Relative Expression (log2-ratio):2.3244896
Number of Samples:4 / 6
Experimental rosuvastatin study 1 (48h)
Hepatocytes treated with 10 mmol/l rosuvastatin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:
Control rifampicin study 5 (48h)
Hepatocytes treated with 5 mmol/l rifampicin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:

atorvastatin study 3 (48h) / rifampicin study 5 (48h)

Relative Expression (log2-ratio):2.313198
Number of Samples:6 / 6
Experimental atorvastatin study 3 (48h)
Hepatocytes treated with 10 mmol/l atorvastatin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:
Control rifampicin study 5 (48h)
Hepatocytes treated with 5 mmol/l rifampicin for 48 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:

azathioprine study 8 (48h) / vehicle (DMSO) treated HepG2 cell sample

Relative Expression (log2-ratio):-2.1808643
Number of Samples:2 / 19
Experimental azathioprine study 8 (48h)
HepG2 cells exposed to 250μM azathioprine in DMSO solvent for 48 hours. ATC code:
Control vehicle (DMSO) treated HepG2 cell sample
HepG2 cells exposed to DMSO solvent for 48 hours.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.175064
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

uterine/pelvic pathology study 2 (pro. MCP) / uterine/pelvic pathology study 2 (late se MCP)

Relative Expression (log2-ratio):2.1563025
Number of Samples:15 / 2
Experimental uterine/pelvic pathology study 2 (pro. MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the proliferative menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control uterine/pelvic pathology study 2 (late se MCP)
Endometrial tissue samples collected from women with uterine/pelvic pathology in the late secretory menstrual cycle phase (MCP). The group contained cycling women 20 – 50 years old with symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.

rosuvastatin study 1 (24h) / rifampicin study 5 (24h)

Relative Expression (log2-ratio):2.1152372
Number of Samples:6 / 6
Experimental rosuvastatin study 1 (24h)
Hepatocytes treated with 10 mmol/l rosuvastatin for 24 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:
Control rifampicin study 5 (24h)
Hepatocytes treated with 5 mmol/l rifampicin for 24 hours. Cells were serum deprivated for 48 hours before treatment. ATC code:

TNF-ɑ; IL-1b; IL-6; PGE2 study 1 / control antibody treated immature dendritic cell sample

Relative Expression (log2-ratio):2.1069136
Number of Samples:4 / 5
Experimental TNF-ɑ; IL-1b; IL-6; PGE2 study 1
Immature dendritic cells (DCs) treated with inflammatory cytokine cocktail (10 ng/ml IL-1b, 1,000 U/ml IL-6, 10 ng/ml TNF-ɑ, 1μg/ml prostaglandin E2) for 24 h.
Control control antibody treated immature dendritic cell sample
Immature dendritic cells (DCs) treated with isotype control antibody (10 - 20μg/ml mouse IgG1 isotype) for 24 h.

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-2.069171
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

TGF-ß3 study 1 (intermediate) / untreated mesenchymal stem cell sample

Relative Expression (log2-ratio):-1.959691
Number of Samples:6 / 5
Experimental TGF-ß3 study 1 (intermediate)
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were stimulated with 10ng/ml of recombinant TGF-ß3 for 3 days or 7 days. (Warning: Experiment with gender bias).
Control untreated mesenchymal stem cell sample
Cultured mesenchymal stem cells from human bone marrow aspirates of healthy donors. Cells were not treated. (Warning: Experiment with gender bias).